Agios Pharmaceuticals.
a public American pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 48
What's happening
Earlier this month
-
Bank of America, Royal Bank of Canada, and Truist Financial raised price targets for Agios Pharmaceuticals on July 31, 2026.Some support3 reports
-
Competitors Agios Pharmaceuticals and Incyte are being compared based on their financial metrics.Some support2 reports
-
Trump's pledge to unleash oil and gas benefits certain stocks.Some support44 reports4 developments inside
One to three months ago
-
Manufacturers Life Insurance Company reduced its stake in Agios Pharmaceuticals and filed the transaction with the SEC.Some support1 report
-
Direct market comparison of financial health between Agios Pharmaceuticals and DT Cloud Star Acquisition Corp.Some support1 report
-
Agios Pharmaceuticals is seeking regulatory approval for its drug candidates from the FDA.Some support1 report
Gone quiet
No new reports in 90+ days-
Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.Well supported3 reports
-
The FDA is reviewing the label expansion application for Pyrukynd, a drug involving Agios Pharmaceuticals and Phathom Pharmaceuticals, Inc.Some support1 report
-
Agios Pharmaceuticals, located in Cambridge, Mass., has identified its corporate structure and key personnel.Some support2 reports
-
FDA adverse event reports led to a stock drop for Agios Pharmaceuticals, which was reported by investing.com.Some support1 report
-
Agios Pharmaceuticals is preparing for potential product launches in Europe and the Gulf region, including Saudi Arabia and the UAE.Some support1 report
-
FDA extended PDUFA goal date for PYRUKYND and Agios submitted REMS to mitigate hepatocellular injury risk.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Agios Pharmaceuticals this week
News at the entities that move Agios Pharmaceuticals most-
FDA StructuralForbes named Elizabeth Holmes one of the richest women, while Theranos claimed FDA approval for its Herpes test.Moves Agios Pharmaceuticals
-
Securities and Exchange Commission StructuralW. R. Berkley Corporation filed its earnings release with the Securities and Exchange Commission on October 1, 2026.Moves Agios Pharmaceuticals
-
SEC StructuralKeefe, Bruyette & Woods raised a price target while First Western Financial disclosed a CEO stock sale filing with the SEC.Moves Agios Pharmaceuticals
-
Truist Financial TransactionalTruist Financial analysts dropped the target price for Deckers Outdoor on July 24, 2026.Moves Agios Pharmaceuticals
-
Manufacturers Life Insurance Company TransactionalTanager Wealth Management LLP acquired a new position and increased its stake in the Invesco International Corporate Bond ETF.Moves Agios Pharmaceuticals
-
DoorDash OperationalDoorDash is using TikTok for promotion while Matt Walsh calls for the company's shutdown.Moves Agios Pharmaceuticals
Connections
The 13 strongest of 48, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates Agios Pharmaceuticals, overseeing drug approvals, label expansions, and adverse event reporting.
-
Sarah Gheuens Structural
Sarah Gheuens serves as Chief Medical Officer and Head of R&D at Agios Pharmaceuticals.
-
Securities and Exchange Commission Structural
Agios Pharmaceuticals operates under the regulatory oversight and reporting requirements of the SEC.
-
SEC Structural
Agios Pharmaceuticals is subject to regulatory oversight by the SEC, requiring the filing of disclosures.
-
Truist Financial Transactional
Truist Financial provides financial analysis and adjusts its price targets for Agios Pharmaceuticals stock.
-
Manufacturers Life Insurance Company Transactional
Manufacturers Life Insurance Company reduced its ownership stake in Agios Pharmaceuticals.
-
Incyte Operational
Agios Pharmaceuticals and Incyte are direct competitors in the healthcare sector, often compared on financial metrics.
-
TipRanks Mentioned together
The entities are co-mentioned in the context of market coverage tracked via financial services.
Show all 13 connections
-
Cambridge Shared context
Agios Pharmaceuticals is headquartered in Cambridge, Massachusetts.
-
Novo Nordisk Operational
The two companies are direct competitors regarding the oral pyruvate kinase-R activator market.
-
DoorDash Operational
The relationship is labeled as competitive, suggesting ongoing market interaction between the two companies.
-
Bank of America Mentioned together
Bank of America provided an analyst rating update on Agios Pharmaceuticals' stock.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada raised a price target on the stock of Agios Pharmaceuticals.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
2 eventsJuly 2026
3 events- Bank of America, Royal Bank of Canada, and Truist Financial raised price targets for Agios Pharmaceuticals on July 31, 2026.
- Agios Pharmaceuticals is seeking regulatory approval for its drug candidates from the FDA.
- Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.
Show 1 earlier month
June 2026
6 events- Trump's pledge to unleash oil and gas benefits certain stocks.
- The FDA is reviewing the label expansion application for Pyrukynd, a drug involving Agios Pharmaceuticals and Phathom Pharmaceuticals, Inc.
- Agios Pharmaceuticals, located in Cambridge, Mass., has identified its corporate structure and key personnel.
- FDA adverse event reports led to a stock drop for Agios Pharmaceuticals, which was reported by investing.com.
- Agios Pharmaceuticals is preparing for potential product launches in Europe and the Gulf region, including Saudi Arabia and the UAE.
- FDA extended PDUFA goal date for PYRUKYND and Agios submitted REMS to mitigate hepatocellular injury risk.